Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Switzerland-based Roche (RHHBY - Analyst Report) recently announced a few changes in its Corporate Executive Committee. 

John C. Reed will now head the Pharma Research and Early Development (pRED) division at Roche as the current ad interim head at pRED, Mike Burgess, will quit Roche. 
 
Reed will also become a member of the expanded Corporate Executive Committee. He will take over Burgess's position on April 2, 2013 in Basel and report to Severin Schwan, Chief Executive Officer (CEO) of the Roche Group. 
 
Reed is a world renowned scientist with a focus on cancer, neuroprotection, autoimmunity, and other diseases. He has led the Sanford-Burnham Medical Research Institute in La Jolla, California. 
 
Inventing more than 100 patents, Reed is a veteran in the pharma industry. He has been a member of multiple scientific journal editorial boards along with founding and co-founding a number of biotechnology companies.
 
Given his sound background in pharma, Roche expects Reed’s appointment as the head of pRED to propel Roche’s strategy of translating an improved understanding of disease mechanisms into promising therapeutics. 
 
Meanwhile, the change of helm at pRED is not expected to affect  the other research division – The Genentech Research and Early Development organization (gRED).
 
We note that Roche announced a few changes in its Corporate Executive Committee in Aug 2012 as well. 
 
Daniel O’Day was appointed as Chief Operating Officer (COO) of Roche Pharma effective Sep 1, 2012. He succeeded Pascal Soriot, who quit Roche to join AstraZeneca ((AZN - Analyst Report)). O’Day has been with Roche since 1987 and has been quite instrumental in building up synchronization between the two divisions – pharma and diagnostics.
 
Prior to being appointed the COO of Roche Pharma, O’Day was the COO of Roche Diagnostics. O’Day was succeeded in that role by Roland Diggelmann, head of the Asia-Pacific Region within Roche Diagnostics. 
 
Currently, Roche expects total revenue as well as revenue from the Pharmaceuticals unit to grow in the low-to-mid single digits in 2012. Sales from the other division, Diagnostics is expected to outperform the market in 2012. 
 
We currently have a Zacks Rank #3 (Hold) on Roche. Pharma stocks that currently look more attractive include Novartis ((NVS - Snapshot Report)) and Sanofi ((SNY - Analyst Report)). Both companies carry a Zacks Rank #2 (Buy).  

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%